Schleiger Anastasia, Nordmeyer Johannes, Kramer Peter, Berger Felix
Department of Congenital Heart Disease/Pediatric Cardiology, German Heart Center Charité, Augustenburger Platz 1, 13353 Berlin, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Germany.
Eur Heart J Case Rep. 2023 Jan 17;7(1):ytad030. doi: 10.1093/ehjcr/ytad030. eCollection 2023 Jan.
Transcatheter correction of superior sinus venosus atrial septal defect (SVASD) with partial anomalous pulmonary venous drainage (PAPVD) of the right upper and/or right middle pulmonary vein (RUPV/RMPV) has recently been described as an alternative to surgical approach in a substantial number of patients. We describe a modified technical approach for transcatheter correction of SVASD using transoesophageal echocardiography (TOE) to confirm adequate stent landing zone and apposition and evaluate its feasibility, safety, and procedural success.
From 2019 to 2021, three consecutive patients received a transcatheter correction of SVASD with PAPVD by redirecting the superior vena cava and RUPV/RMPV to the left atrium by implantation of a custom-made covered Cheatham platinum stent (10-zig, length: 60-80 mm). Prior to stent implantation, a balloon testing was performed in the anticipated landing zone using TOE to confirm complete defect closure and unobstructed pulmonary venous drainage. Stent deployment and flaring of the interior stent portion were performed with TOE guidance to confirm adequate landing zone and apposition and to avoid residual shunt or pulmonary vein obstruction.
Transcatheter correction of SVASD with PAPVD was performed without any complications. The follow-up period was 7.8, 13.6, and 29.8 months, respectively. During follow-up, no mortality, stent embolization, or obstruction of pulmonary venous drainage occurred. The TOE-guided modified transcatheter approach for correction of SVASD with PAPVD is safe and feasible with excellent post-procedural results and represents an alternative to surgical treatment in a pre-selected patient cohort.
经导管矫正上腔静脉窦型房间隔缺损(SVASD)合并右上和/或右中肺静脉(RUPV/RMPV)部分性肺静脉异位引流(PAPVD),最近已被描述为许多患者手术治疗的替代方法。我们描述了一种改良的经导管矫正SVASD的技术方法,使用经食管超声心动图(TOE)来确认支架合适的着陆区和贴靠情况,并评估其可行性、安全性和手术成功率。
2019年至2021年,连续3例患者接受了经导管矫正SVASD合并PAPVD的治疗,通过植入定制的带膜Cheatham铂金支架(10-Zig,长度:60-80 mm)将上腔静脉和RUPV/RMPV重定向至左心房。在植入支架之前,使用TOE在预期的着陆区进行球囊测试,以确认缺损完全闭合和肺静脉引流通畅。在TOE引导下进行支架展开和内部支架部分的扩张,以确认合适的着陆区和贴靠情况,并避免残余分流或肺静脉梗阻。
经导管矫正SVASD合并PAPVD未发生任何并发症。随访期分别为7.8、13.6和29.8个月。随访期间,未发生死亡、支架栓塞或肺静脉引流梗阻。TOE引导下改良的经导管矫正SVASD合并PAPVD的方法安全可行,术后效果良好,是预选患者队列中手术治疗的替代方法。